Pembrolizumab + Belzutifan + Pembrolizumab/Quavonlimab + Lenvatinib
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Renal Cell
Conditions
Carcinoma, Renal Cell
Trial Timeline
Jul 27, 2022 → Jun 7, 2027
NCT ID
NCT05899049About Pembrolizumab + Belzutifan + Pembrolizumab/Quavonlimab + Lenvatinib
Pembrolizumab + Belzutifan + Pembrolizumab/Quavonlimab + Lenvatinib is a phase 3 stage product being developed by Eisai for Carcinoma, Renal Cell. The current trial status is active. This product is registered under clinical trial identifier NCT05899049. Target conditions include Carcinoma, Renal Cell.
What happened to similar drugs?
20 of 20 similar drugs in Carcinoma, Renal Cell were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05899049 | Phase 3 | Active |
| NCT04736706 | Phase 3 | Active |
Competing Products
20 competing products in Carcinoma, Renal Cell